Skip to main content

Advertisement

Table 3 Overall objective response according to scheme of therapy

From: Acquired activated protein C resistance and thrombosis in multiple myeloma patients

Scheme N %
VAD 20 40
Overall objective response 11/20 55
Thalidomide plus dexamethasone 24 48
Overall objective response 18/24 75
Melphalan plus prednisone 6 12
Overall objective response 2/6 33